Medical News: ECCO-ESMO: Spikes in Liver Enzymes Common in Ovarian Cancer Tx (Trabectedin / Yondelis)

Action Points

---

• Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.



• Explain that liver transaminase abnormalities in patients with advanced ovarian cancer who received trabectedin did not impact outcomes, including response rate.



• Note that liver transaminase abnormalities were seen in 63% of patients studied.